(NASDAQ: CRIS) Curis's forecast annual revenue growth rate of 71.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Curis's revenue in 2026 is $9,443,000.On average, 6 Wall Street analysts forecast CRIS's revenue for 2026 to be $452,638,762, with the lowest CRIS revenue forecast at $391,791,191, and the highest CRIS revenue forecast at $495,336,006. On average, 6 Wall Street analysts forecast CRIS's revenue for 2027 to be $804,851,047, with the lowest CRIS revenue forecast at $458,395,694, and the highest CRIS revenue forecast at $1,637,127,478.
In 2028, CRIS is forecast to generate $2,069,497,043 in revenue, with the lowest revenue forecast at $881,530,181 and the highest revenue forecast at $3,316,232,584.